Intramuscular Testosterone Undecanoate: Pharmacokinetic Aspects of a Novel Testosterone Formulation during Long-Term Treatment of Men with Hypogonadism
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
In an open-label, randomized, prospective trial, we investigated pharmacokinetics and several efficacy and safety parameters of a novel, long-acting testosterone (T) undecanoate (TU) formulation in 40 hypogonadal men (serum testosterone concentrations < 5 nmol/liter). For the first 30 wk (comparative study), the patients were randomly assigned to receive either 10 x 250 mg T enanthate (TE) im every 3 wk (n = 20) or 3 x 1000 mg TU im every 6 wk (loading dose) followed by 1 x 1000 mg after an additional 9 wk (n = 20). In a follow-up study, observation continued in those patients who completed the comparative part and opted for TU treatment (8 x 1000 mg TU every 12 wk in former TU patients and 2 x 1000 mg TU every 8 wk plus 6 x 1000 mg every 12 wk in former TE patients) for an additional 20-21 months. Here we report only the pharmacokinetic aspects of the new TU formulation for the first approximately 2.5 yr of treatment. At baseline, serum T concentrations did not significantly differ between the two study groups. In the TE group, mean trough levels of serum T were always less than 10 nmol/liter before the next injection, whereas in the TU group, mean trough levels of serum T were 14.1 +/- 4.5 nmol/liter after the first two doses (6-wk intervals) and 16.3 +/- 5.7 nmol/liter after the 9-wk interval at wk 30. The mean serum levels of dihydrotestosterone and estradiol also increased in parallel to the serum T pattern and remained within the normal range. In the follow-up study, the former TU patients (n = 20) received eight TU injections at 12-wk intervals, and the TE patients (n = 16) switched to TU and initially received two TU injections at 8-wk intervals (loading) and continued with six TU injections at 12-wk intervals (maintenance). This regimen resulted in stable mean serum trough levels of T (ranging from 14.9 +/- 5.2 to 16.5 +/- 8.0 nmol/liter) and estradiol (ranging from 98.5 +/- 45.2 to 80.4 +/- 14.4 pmol/liter). The present study has shown that 1000 mg TU injected into male patients with hypogonadism at 12-wk intervals is well tolerated and leads to T levels within normal ranges, using four instead of 17 or more TE injections per year. An initial loading dose of either 3 x 1000 mg TU every 6 wk at the beginning of hormone substitution or 2 x 1000 mg TU every 8 wk after switching from the short-acting TE to TU were found to be a adequate dosing regimens for starting of treatment with the long-acting TU preparation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nieschlag, E., Büchter, D., Von Eckardstein, S., Abshagen, K., Simoni, M., & Behre, H. M. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00881.x · Cited by 140
Cited by
Schneider, H. J., Aimaretti, G., Kreitschmann-Andermahr, I., Stalla, G.-K., & Ghigo, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60673-4 · Cited by 336
Traish, A. M., Goldstein, I., & Kim, N. N. (2007) · European Urology · doi:10.1016/j.eururo.2007.02.034 · Cited by 268
Endocrine Aspects of Male Sexual Dysfunctions
Buvat, J., Maggi, M., Gooren, L., Guay, A. T., Kaufman, J., Morgentaler, A., Schulman, C., Tan, H. M., Torres, L. O., Yassin, A., et al. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01780.x · Cited by 221
Zitzmann, M., & Nieschlag, E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0620 · Cited by 216
Testosterone for the aging male; current evidence and recommended practice
Jones, H. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s190 · Cited by 204
Hackett, G., Cole, N., Bhartia, M., Kennedy, D., Raju, J., & Wilkinson, P. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12146 · Cited by 182
Erythrocytosis Following Testosterone Therapy
Ohlander, S. J., Varghese, B., & Pastuszak, A. W. (2018) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.04.001 · Cited by 168
Hackett, G., Cole, N., Bhartia, M., Kennedy, D., Raju, J., Wilkinson, P., & the BLAST Study Group (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12404 · Cited by 168
Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism
Jayasena, C. N., Anderson, R. A., Llahana, S., Barth, J. H., MacKenzie, F., Wilkes, S., Smith, N., Sooriakumaran, P., Minhas, S., Wu, F. C. W., et al. (2022) · Clinical Endocrinology · doi:10.1111/cen.14633 · Cited by 147
Outcomes of clomiphene citrate treatment in young hypogonadal men
Katz, D. J., Nabulsi, O., Tal, R., & Mulhall, J. P. (2012) · BJU International · doi:10.1111/j.1464-410x.2011.10702.x · Cited by 142
Giltay, E. J., Tishova, Y. A., Mskhalaya, G. J., Gooren, L. J. G., Saad, F., & Kalinchenko, S. Y. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01859.x · Cited by 140
Saad, F., Gooren, L. J., Haider, A., & Yassin, A. (2008) · Journal of Andrology · doi:10.2164/jandrol.107.002774 · Cited by 132
Ng Tang Fui, M., Prendergast, L. A., Dupuis, P., Raval, M., Strauss, B. J., Zajac, J. D., & Grossmann, M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0700-9 · Cited by 124
Hoyos, C. M., Killick, R., Yee, B. J., Grunstein, R. R., & Liu, P. Y. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04413.x · Cited by 118
Defreyne, J., Vantomme, B., Van Caenegem, E., Wierckx, K., De Blok, C. J. M., Klaver, M., Nota, N. M., Van Dijk, D., Wiepjes, C. M., Den Heijer, M., et al. (2018) · Andrology · doi:10.1111/andr.12485 · Cited by 114
“Administration of testosterone undecanoate, an oil vehiclebased formulation which is injected intramuscularly every 12 weeks, results in more stable serum concentrations than intramuscular injections with testosterone esters (Schubert et al., 2004).”
BackgroundImprovement of Sexual Function in Men with Late-Onset Hypogonadism Treated with Testosterone Only
Yassin, A. A., & Saad, F. (2007) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2007.00442.x · Cited by 101
Saad, F., Gooren, L., Haider, A., & Yassin, A. (2008) · Andrologia · doi:10.1111/j.1439-0272.2008.00807.x · Cited by 89
Saad, F., Gooren, L., Haider, A., & Yassin, A. (2007) · Archives of Andrology · doi:10.1080/01485010701730880 · Cited by 87
Jacobeit, J. W., Gooren, L. J., & Schulte, H. M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0412 · Cited by 73
Ho, C. C. K., Tong, S. F., Low, W. Y., Ng, C. J., Khoo, E. M., Lee, V. K. M., Zainuddin, Z. M., & Tan, H. M. (2012) · BJU International · doi:10.1111/j.1464-410x.2011.10755.x · Cited by 53
Zitzmann, M., Erren, M., Kamischke, A., Simoni, M., & Nieschlag, E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0847 · Cited by 49
“The optimal injection interval for the treatment of hypogonadal men is set between 10 and 14 wk (23).”
BackgroundMoon, D. G., Park, M. G., Lee, S. W., Park, K., Park, J. K., Kim, S. W., Park, N. C., Ahn, T. Y., Paick, J. S., Seo, J. T., et al. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01765.x · Cited by 46
Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood
Jockenhövel, F., Minnemann, T., Schubert, M., Freude, S., Hübler, D., Schumann, C., Christoph, A., Gooren, L., & Ernst, M. (2009) · The Aging Male · doi:10.3109/13685530903322858 · Cited by 31
“As reported earlier [3] in the TE group, mean trough levels of serum T were always less than 10 nmol/l before the next injection, whereas in the TU group, mean trough levels of serum T were 14.”
BackgroundSelf-citationTestosterone Therapy for Osteoporosis in Men
Lakshman, K. M., Bhasin, S., & Araujo, A. B. (2010) · Osteoporosis in Men · doi:10.1016/b978-0-12-374602-3.00056-0 · Cited by 1
Metadata
- Authors
- Schubert, M., Minnemann, T., Hübler, D., Rouskova, D., Christoph, A., Oettel, M., Ernst, M., Mellinger, U., Krone, W., & Jockenhövel, F.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-11
- Volume
- 89
- Issue
- 11
- Pages
- 5429-5434
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2078753971
- Cited by
- 188
- References
- 1
- FWCI
- 8.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.